Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

04. Januar 2018 08:00 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences Initiates Phase 2/3 Trial of Marzeptacog Alfa (activated) for Prophylaxis in Hemophilia A or B with Inhibitors

Currently Enrolling Individuals with Hemophilia A or B with Inhibitors Interim Data Expected During the First Half of 2018 SOUTH SAN FRANCISCO, Calif., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Catalyst...
22. Dezember 2017 12:15 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Closing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address...
20. Dezember 2017 09:11 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address...
19. Dezember 2017 16:51 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address...
18. Dezember 2017 08:00 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Acceleration of Phase 1/2 Trial of CB 2679d/ISU304 in Individuals with Hemophilia B

Korean Ministry of Food and Drug Safety Approves Omitting Cohort 4 and Dosing Cohort 5 with Six Daily Subcutaneous Doses of Next-Generation Coagulation Factor IX Current lower doses are predicted...
14. Dezember 2017 08:30 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Appointment of Edward Williams to its Board of Directors

Former Novo Nordisk Executive Strengthens Catalyst’s Hemophilia Expertise SOUTH SAN FRANCISCO, Calif., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (Nasdaq:CBIO), a clinical-stage...
11. Dezember 2017 08:00 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Interim Phase 1/2 CB 2679d/ISU304 Results at the American Society of Hematology Conference

Subcutaneous (SQ) delivery significantly increases half-life of CB 2679d to 98.7 hours Data supports potential normalization of FIX activity with daily or less-frequent SQ dosing SOUTH SAN...
09. Dezember 2017 09:30 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Interim Phase 1/2 CB 2679d/ISU304 Results at the American Society of Hematology Conference

Subcutaneous (SQ) delivery significantly increases half-life of CB 2679d to 98.7 hours Data supports potential normalization of FIX activity with daily or less-frequent SQ dosing SOUTH SAN...
28. November 2017 08:30 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences Strengthens Clinical Hemophilia Programs with Additions to its Senior Leadership Team

-- Appoints Arwa Shurrab as Vice President of Regulatory Affairs and Jamie Ellen Siegel, M.D., as Head of Clinical Development -- SOUTH SAN FRANCISCO, Calif., Nov. 28, 2017 (GLOBE NEWSWIRE) --...
02. November 2017 08:30 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences Reports Third Quarter 2017 Operating & Financial Results and Provides Corporate Update

-- Phase 1/2 trial of Factor IX CB 2679d is advancing with interim results expected by year-end -- -- Phase 2 trial of Factor FVIIa marzeptacog alfa (activated) on track for initiation by year-end-- ...

Vorherige Seite